Frontotemporal dementia, where do we stand? A narrative review

A Antonioni, EM Raho, P Lopriore, AP Pace… - International journal of …, 2023‏ - mdpi.com
Frontotemporal dementia (FTD) is a neurodegenerative disease of growing interest, since it
accounts for up to 10% of middle-age-onset dementias and entails a social, economic, and …

Nanoparticle-based drug delivery systems: an inspiring therapeutic strategy for neurodegenerative diseases

L Duan, X Li, R Ji, Z Hao, M Kong, X Wen, F Guan… - Polymers, 2023‏ - mdpi.com
Neurodegenerative diseases are common, incurable neurological disorders with high
prevalence, and lead to memory, movement, language, and intelligence impairments …

Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results

J Sevigny, O Uspenskaya, LD Heckman, LC Wong… - Nature Medicine, 2024‏ - nature.com
GRN mutations cause progranulin haploinsufficiency, which eventually leads to
frontotemporal dementia (FTD-GRN). PR006 is an investigational gene therapy delivering …

The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology

M Benatar, J Wuu, ED Huey, CT McMillan… - Nature Reviews …, 2024‏ - nature.com
Increasing appreciation of the phenotypic and biological overlap between amyotrophic
lateral sclerosis (ALS) and frontotemporal dementia, alongside evolving biomarker evidence …

[HTML][HTML] Unraveling the impact of Omega-3 polyunsaturated fatty acids on blood-brain barrier (BBB) integrity and glymphatic function

J Wen, SK Satyanarayanan, A Li, L Yan, Z Zhao… - Brain, Behavior, and …, 2024‏ - Elsevier
Alzheimer's disease (AD) and other forms of dementia represent major public health
challenges but effective therapeutic options are limited. Pathological brain aging is …

Alzheimer's disease early diagnostic and staging biomarkers revealed by large-scale cerebrospinal fluid and serum proteomic profiling

QQ Tao, X Cai, YY Xue, W Ge, L Yue, XY Li, RR Lin… - The Innovation, 2024‏ - cell.com
Amyloid-β, tau pathology, and biomarkers of neurodegeneration make up the core
diagnostic biomarkers of Alzheimer disease (AD). However, these proteins represent only a …

A survey of deep learning for Alzheimer's disease

Q Zhou, J Wang, X Yu, S Wang, Y Zhang - Machine learning and …, 2023‏ - mdpi.com
Alzheimer's and related diseases are significant health issues of this era. The
interdisciplinary use of deep learning in this field has shown great promise and gathered …

[HTML][HTML] The gut microbiome–brain crosstalk in neurodegenerative diseases

L Ghezzi, C Cantoni, E Rotondo, D Galimberti - Biomedicines, 2022‏ - mdpi.com
The gut–brain axis (GBA) is a complex interactive network linking the gut to the brain. It
involves the bidirectional communication between the gastrointestinal and the central …

Amyloid and tau positron emission tomography imaging in Alzheimer's disease and other tauopathies

C Maschio, R Ni - Frontiers in aging neuroscience, 2022‏ - frontiersin.org
The detection and staging of Alzheimer's disease (AD) using non-invasive imaging
biomarkers is of substantial clinical importance. Positron emission tomography (PET) …

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

X Zhang, J Wang, Z Zhang, K Ye - Translational Neurodegeneration, 2024‏ - Springer
The deposition of abnormal tau protein is characteristic of Alzheimer's disease (AD) and a
class of neurodegenerative diseases called tauopathies. Physiologically, tau maintains an …